Friday, October 30, 2026

AI Video Generation Costs Drop 98% as Enterprise Tools Hit $847M Market

AI video generation costs fell from hundreds of dollars per minute in 2024 to single digits in 2026, driving enterprise adoption toward an $847 million global market. Production teams that required 50-100 people now operate with fewer than 10. Four platforms—Google's Veo 3.1, OpenAI, and two others—dominate the consolidating sector.

AI Video Generation Costs Drop 98% as Enterprise Tools Hit $847M Market
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Per-minute AI video generation costs dropped from several hundred dollars in 2024 to single-digit dollars in 2026, compressing production economics by over 98%. The cost collapse is driving the sector from research labs into commercial deployment, with global revenue projected at $847 million for 2026.

Production capabilities that previously required teams of 50-100 professionals now run with fewer than 10 people. This workforce compression creates direct margin expansion for early adopters while threatening traditional video production studios operating at legacy cost structures.

The competitive landscape has consolidated around four principal platforms: Google's Veo 3.1, OpenAI, and two undisclosed providers. Cuty AI announced a unified image and video creation platform on February 9, 2026, joining the race for enterprise contracts.

Enterprises evaluating platforms face switching costs that lock in early provider choices, giving first movers in Google and OpenAI structural advantages. Smaller platforms must differentiate on vertical specialization or risk acquisition.

Investment implications split three ways. Platform providers with proven enterprise traction capture revenue growth. Video production companies face margin pressure unless they pivot to AI-augmented workflows. Content-heavy industries—advertising, entertainment, corporate communications—gain cost arbitrage opportunities worth monitoring in Q1-Q2 earnings.

The Q1-Q2 2026 period serves as a test window. Enterprise adoption rates, market share distribution among the top four providers, and team size reductions at production companies will validate whether cost compression translates to sustainable business transformation or temporary arbitrage.

For investors, the sector presents asymmetric risk. Platform winners could scale rapidly as production costs approach zero marginal expense. Traditional production studios holding physical assets and large payrolls face structural disadvantage. The $847 million 2026 market represents early-stage deployment; enterprise budgets shifting from human labor to software licenses could multiply that figure by 2027.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com